Cognition Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cognition Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was -$164.00K.
- Cognition Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $2.31M.
- Cognition Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $5.18M, a 88.28% decline from fiscal 2021.
- Cognition Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $44.22M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | -$164.00K 10-Q · filed 2026-08-07 | |
| 2023-06-30 | $2.31M 10-Q · filed 2023-11-02 | |
| 2022-12-31 | $5.18M 10-K · filed 2024-03-26 | |
| 2021-12-31 | $44.22M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |